title: Evidence for a novel thrombopoietin signalling event: activation of protein kinase A in human megakaryoblastic CMK cells.
abstract: Thrombopoietin (TPO) plays a crucial role in megakaryocyte development. TPO signalling, which is mediated by its receptor Mpl, includes Janus kinase, (JAK) signal transducer and activator of transcription (STAT) and Shc/Ras/mitogen-activated protein kinase (MAPK) pathways. The precise nature of these signalling routes has not been clarified in detail up until now. We investigated the effect of TPO on activation of cAMP-dependent protein kinase (PKA) and its involvement in MAPK signalling in human megakaryoblastic leukaemia CMK cells. For estimation of PKA activity, phosphorylation of a PKA-specific peptide substrate was assayed in CMK cell lysates. Since activation of PKA is associated with translocation of its catalytic subunit alpha (C-PKA) into the cell nucleus, Western blot analysis of nuclear fractions with an anti-C-PKA antibody was additionally performed. The activation of TPO-induced MAPK activation and the effect of the PKA inhibitor H-89 was measured using immunoblotting with a monoclonal anti-pERK antibody. TPO enhanced cAMP and induced activation of PKA in CMK cells. In addition, H-89 partly blocked TPO-induced MAPK activation in CMK cells. Our results indicate a novel TPO-triggered signalling event, activation of the cAMP/PKA pathway in human megakaryoblastic CMK cells. This signal transduction route seems to be involved in TPO-induced MAPK signaling.
authors.affiliation: Division of Pediatric Hematology-Oncology, Medical School, University of Minnesota, MN, USA.
authors.forename: M
authors.initials: M
authors.lastname: Sauer
authors.forename: S
authors.initials: S
authors.lastname: Tausch
authors.forename: M
authors.initials: M
authors.lastname: Zieger
authors.forename: F
authors.initials: F
authors.lastname: Zintl
authors.forename: G
authors.initials: G
authors.lastname: Nowak
authors.forename: R
authors.initials: R
authors.lastname: Kaufmann
mesh_terms: D002467:Cell Nucleus / Q000378:metabolism; D000242:Cyclic AMP / Q000819:agonists / Q000378:metabolism*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D004789:Enzyme Activation; D006801:Humans; D007546:Isoquinolines / Q000037:antagonists & inhibitors / Q000378:metabolism; D007947:Leukemia, Megakaryoblastic, Acute / Q000378:metabolism*; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D021381:Protein Transport / Q000187:drug effects / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D013449:Sulfonamides; D013926:Thrombopoietin / Q000378:metabolism* / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D007546:Isoquinolines; D013449:Sulfonamides; D013926:Thrombopoietin; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D020928:Mitogen-Activated Protein Kinases; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide